Literature DB >> 2297481

Direct search methods in the optimisation of cancer chemotherapy regimens.

M C Berenbaum1.   

Abstract

Current cancer chemotherapy regimens may involve 20-30 or more independent variables, each affecting therapeutic response and toxicity. With standard response surface modelling methods, finding the optimum combination with as few as 10 variables entails testing over 1,000 combinations, so these methods do not provide a feasible approach to such problems. However, they may be tackled by direct search methods (DSM), i.e. stepwise searches of the response surface. Experiments were carried out in advanced L1210 leukaemia treated with combinations of adriamycin with cyclophosphamide, isophosphamide with acetylcysteine and methotrexate with leucovorin. Two established DSM (Nelder-Mead and Box) were used, and a new method was designed to find consistent search paths in spite of wide biological variation. With methotrexate and leucovorin, DSM located combinations prolonging mean survival to 40-50 days (compared with 10.4 in controls) and giving high proportions of long-term survivors. These results were achieved with single injections of drugs given 7 days after injection of 10(6) leukaemic cells, i.e. 2-3 days before deaths began in untreated mice, and appear to be unprecedented with these agents. Searching for optimal combinations of established agents may be at least as rewarding as searching for new agents, and thus DSM may prove a powerful tool for improving the results of combination cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297481      PMCID: PMC1971319          DOI: 10.1038/bjc.1990.22

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

Authors:  H E SKIPPER; F M SCHABEL; W S WILCOX
Journal:  Cancer Chemother Rep       Date:  1964-02

2.  Quantitative evaluation of chemotherapeutic agents against advanced leukemia in mice.

Authors:  A GOLDIN; J M VENDITTI; S R HUMPHREYS; N MANTEL
Journal:  J Natl Cancer Inst       Date:  1958-09       Impact factor: 13.506

3.  Estimation and analysis of the concentration-response surfaces associated with multiple-agent combinations.

Authors:  R P Solana; V M Chinchilli; J Wilson; W H Carter; R A Carchman
Journal:  Toxicol Appl Pharmacol       Date:  1986-09-15       Impact factor: 4.219

4.  Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.

Authors:  I Kline; M Gang; R J Woodman; R L Cysyk; J M Venditti
Journal:  Cancer Chemother Rep       Date:  1973 Sep-Oct

5.  Application of response-surface methodology to detect interactions of genotoxic agents in cultured mammalian cells.

Authors:  J D Wilson; W H Carter; E D Campbell; F K Kessler; R A Carchman
Journal:  J Toxicol Environ Health       Date:  1986

6.  Identical efficacy of methotrexate regimens with N5-methyltetrahydrofolate rescue or with leucovorin rescue for treatment of L1210 murine leukemia.

Authors:  P F Nixon; L Wilson
Journal:  Cancer Treat Rep       Date:  1983-01

7.  Drug activity and therapeutic synergism in cancer treatment.

Authors:  W H Carter; G L Wampler; D M Stablein; E D Campbell
Journal:  Cancer Res       Date:  1982-08       Impact factor: 12.701

8.  Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.

Authors:  T L Avery; D Roberts
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

9.  Application of response surface methods for evaluating the interactions of soman, atropine, and pralidioxime chloride.

Authors:  W H Carter; D E Jones; R A Carchman
Journal:  Fundam Appl Toxicol       Date:  1985-12

10.  Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.

Authors:  J S Tobias; L M Parker; M H Tattersall; E Frei
Journal:  Br J Cancer       Date:  1975-08       Impact factor: 7.640

View more
  2 in total

1.  Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

Authors:  S J DeNardo; D L Kukis; L A Kroger; R T O'Donnell; K R Lamborn; L A Miers; D G DeNardo; C F Meares; G L DeNardo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

2.  Systematic quantitative characterization of cellular responses induced by multiple signals.

Authors:  Ibrahim Al-Shyoukh; Fuqu Yu; Jiaying Feng; Karen Yan; Steven Dubinett; Chih-Ming Ho; Jeff S Shamma; Ren Sun
Journal:  BMC Syst Biol       Date:  2011-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.